Abstract
Most groups now obtain high cure rates in paediatric extracranial MGCTs, mostly using cisplatin-based chemotherapy [1–4]. In Britain, a carboplatin-based regimen (carboplatin, etoposide and bleomycin — JEB) is preferred because it is less oto- and nephrotoxic [5]. An analysis of the UKCCSG’s second study (GCII) aimed to define risk groups in order to refine therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
